SG11201806342SA - Glucagon and glp-1 co-agonists for the treatment of obesity - Google Patents
Glucagon and glp-1 co-agonists for the treatment of obesityInfo
- Publication number
- SG11201806342SA SG11201806342SA SG11201806342SA SG11201806342SA SG11201806342SA SG 11201806342S A SG11201806342S A SG 11201806342SA SG 11201806342S A SG11201806342S A SG 11201806342SA SG 11201806342S A SG11201806342S A SG 11201806342SA SG 11201806342S A SG11201806342S A SG 11201806342SA
- Authority
- SG
- Singapore
- Prior art keywords
- building
- international
- milstein
- cambridge
- granta park
- Prior art date
Links
- 102000051325 Glucagon Human genes 0.000 title abstract 3
- 108060003199 Glucagon Proteins 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 3
- 229960004666 glucagon Drugs 0.000 title abstract 3
- 235000020824 obesity Nutrition 0.000 title abstract 3
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 102220240796 rs553605556 Human genes 0.000 abstract 4
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 102100040918 Pro-glucagon Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
aVehicle (buffer) * Liraglfffide .6 nmoIrkg • inuArkg 4 GAO 20 nmobkg G730 50 nmol.fkg Bo dy we ig ht ( % c hang e o f day 0) -12 -14 -16 -18 -20 -22 -24 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/153575 Al 14 September 2017 (14.09.2017) WIPO I PCT (51) International Patent Classification: A61K 38/26 (2006.01) A61P 3/10 (2006.01) A61P 3/04 (2006.01) A61P 9/12 (2006.01) A61P 3/06 (2006.01) (21) International Application Number: PCT/EP2017/055679 (22) International Filing Date: 10 March 2017 (10.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/306,121 10 March 2016 (10.03.2016) US (71) Applicant: MEDIMMUNE LIMITED [GB/GB]; Mil- stein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). (72) Inventors: BEDNAREK, Maria, Aleksandra; MedIm- mune Limited Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). JERMUTUS, Lutz, Ul- rich; Milstein Building Granta Park, Cambridge Cam- bridgeshire CB21 6GH (GB). AMBERY, Philip; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). PETRONE, Marcella; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). (74) Agent: TTOFI, Evangelia; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) = (54) Title: GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY 111111111111110111011111111111010111110 III 011110110111100111111111111111111110111111 W O 20 17 / 15 3575 Al 0 1 2 3 4 5 6 7 0 11 12 13 14 Dosing day FIG. 1 (57) : Provided herein are methods of preventing and treating obesity and diabetes in patients comprising administering GLP-1/glucagon agonist peptides.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306121P | 2016-03-10 | 2016-03-10 | |
| PCT/EP2017/055679 WO2017153575A1 (en) | 2016-03-10 | 2017-03-10 | Glucagon and glp-1 co-agonists for the treatment of obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806342SA true SG11201806342SA (en) | 2018-08-30 |
Family
ID=58266629
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806342SA SG11201806342SA (en) | 2016-03-10 | 2017-03-10 | Glucagon and glp-1 co-agonists for the treatment of obesity |
| SG10202109721P SG10202109721PA (en) | 2016-03-10 | 2017-03-10 | Glucagon and glp-1 co-agonists for the treatment of obesity |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202109721P SG10202109721PA (en) | 2016-03-10 | 2017-03-10 | Glucagon and glp-1 co-agonists for the treatment of obesity |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10676517B2 (en) |
| EP (1) | EP3426284B1 (en) |
| JP (2) | JP7237590B6 (en) |
| KR (2) | KR102460198B1 (en) |
| CN (1) | CN108697769A (en) |
| AR (1) | AR107890A1 (en) |
| AU (2) | AU2017229530B2 (en) |
| BR (1) | BR112018067731A2 (en) |
| CA (1) | CA3015922A1 (en) |
| EA (1) | EA201891946A1 (en) |
| IL (1) | IL261528B2 (en) |
| MX (1) | MX2018010640A (en) |
| MY (1) | MY191321A (en) |
| NZ (1) | NZ746784A (en) |
| SG (2) | SG11201806342SA (en) |
| TW (1) | TWI793069B (en) |
| WO (1) | WO2017153575A1 (en) |
| ZA (1) | ZA201806637B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020280905A1 (en) * | 2019-05-21 | 2022-01-06 | Medimmune Limited | Cyclodextrin based injectable coformulations of SGLT2 inhibitors and incretin peptides |
| JP2022539200A (en) | 2019-07-01 | 2022-09-07 | メドイミューン・リミテッド | Pharmaceutical compositions for glucagon and GLP-1 co-agonist peptides |
| EP4017866A1 (en) | 2019-08-19 | 2022-06-29 | Eli Lilly and Company | Methods of making incretin analogs |
| EP4069720A4 (en) * | 2019-12-03 | 2023-12-27 | MedImmune, LLC | Combination therapy using glucagon and glp-1 co-agonists for the treatment of obesity |
| TWI795698B (en) | 2019-12-18 | 2023-03-11 | 美商美國禮來大藥廠 | Incretin analogs and uses thereof |
| TW202140061A (en) * | 2020-01-10 | 2021-11-01 | 英商梅迪繆思有限公司 | Glucagon and glp-1 co-agonists for the treatment of chronic kidney disease and diabetic kidney disease in type 2 diabetes |
| EP4090351A4 (en) * | 2020-01-16 | 2023-09-13 | Shanghai Benemae Pharmaceutical Corporation | Dosing regimen of glp-1 |
| CN113493503B (en) * | 2020-04-08 | 2022-08-05 | 浙江道尔生物科技有限公司 | Incretin analogue and preparation method and application thereof |
| CN115484972A (en) | 2020-04-24 | 2022-12-16 | 勃林格殷格翰国际有限公司 | Glucagon analogs as long-acting GLP-1/glucagon receptor agonists for the treatment of fatty liver disease and steatohepatitis |
| KR20230004135A (en) * | 2021-06-30 | 2023-01-06 | 한미약품 주식회사 | Therapeutic use of a combination comprising a trigonal glucagon/GLP-1/GIP receptor agonist |
| CN117677395A (en) | 2021-07-30 | 2024-03-08 | 勃林格殷格翰国际有限公司 | Dosage regimen for long acting GLP 1/glucagon receptor agonists |
| WO2023225370A1 (en) * | 2022-05-19 | 2023-11-23 | Vault Bioventures, Inc. | Obesity treatment and prevention methods |
| CN115975057B (en) * | 2023-03-16 | 2023-05-16 | 杭州信海医药科技有限公司 | Solid phase synthesis method of trastuzumab |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| CN101970678B (en) | 2007-06-21 | 2014-08-20 | 慕尼黑科技大学 | Biological active proteins having increased in vivo and/or vitro stability |
| FR2932484B1 (en) | 2008-06-16 | 2010-06-18 | Sanofi Aventis | NOVEL PYRROLOINDOLE DERIVATIVES INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME AND USE THEREOF |
| US8546327B2 (en) | 2008-06-17 | 2013-10-01 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| SG177609A1 (en) * | 2009-07-13 | 2012-02-28 | Zealand Pharma As | Acylated glucagon analogues |
| RU2012136450A (en) * | 2010-01-27 | 2014-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | CONJUGATES GLUCAGON ANTAGONIST - GIP AGONIST AND COMPOSITIONS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY |
| CN103370083B (en) | 2010-09-28 | 2016-11-16 | 艾米琳制药有限责任公司 | There is the engineered polypeptide of the acting duration of enhancing |
| AR084558A1 (en) * | 2010-12-22 | 2013-05-22 | Marcadia Biotech | METHODS TO TREAT METABOLIC DISORDERS AND OBESITY WITH ACTIVE GLUCAGON-BASED PEPTIDES FOR THE GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP) / PEPTIDO-1 SIMILAR TO GLUCAGON (GLP-1) |
| EP2694095B1 (en) | 2011-04-05 | 2018-03-07 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
| KR101968344B1 (en) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | A composition for treating hyperlipidemia comprising oxyntomodulin analog |
| TWI674270B (en) * | 2012-12-11 | 2019-10-11 | 英商梅迪繆思有限公司 | Glucagon and glp-1 co-agonists for the treatment of obesity |
| ES2688367T3 (en) * | 2012-12-21 | 2018-11-02 | Sanofi | Derivatives of exendin-4 as dual agonists of GLP1 / GIP or trigonal of GLP1 / GIP / glucagon |
-
2017
- 2017-03-10 JP JP2018546872A patent/JP7237590B6/en active Active
- 2017-03-10 CN CN201780013643.1A patent/CN108697769A/en active Pending
- 2017-03-10 AU AU2017229530A patent/AU2017229530B2/en active Active
- 2017-03-10 US US16/083,064 patent/US10676517B2/en active Active
- 2017-03-10 NZ NZ746784A patent/NZ746784A/en unknown
- 2017-03-10 SG SG11201806342SA patent/SG11201806342SA/en unknown
- 2017-03-10 BR BR112018067731A patent/BR112018067731A2/en unknown
- 2017-03-10 TW TW106108066A patent/TWI793069B/en active
- 2017-03-10 EA EA201891946A patent/EA201891946A1/en unknown
- 2017-03-10 AR ARP170100613A patent/AR107890A1/en unknown
- 2017-03-10 SG SG10202109721P patent/SG10202109721PA/en unknown
- 2017-03-10 WO PCT/EP2017/055679 patent/WO2017153575A1/en active Application Filing
- 2017-03-10 KR KR1020187028772A patent/KR102460198B1/en active IP Right Grant
- 2017-03-10 CA CA3015922A patent/CA3015922A1/en active Pending
- 2017-03-10 KR KR1020227037091A patent/KR20220150416A/en not_active Application Discontinuation
- 2017-03-10 EP EP17710231.6A patent/EP3426284B1/en active Active
- 2017-03-10 MX MX2018010640A patent/MX2018010640A/en unknown
- 2017-03-10 IL IL261528A patent/IL261528B2/en unknown
- 2017-03-10 MY MYPI2018703199A patent/MY191321A/en unknown
-
2018
- 2018-10-05 ZA ZA2018/06637A patent/ZA201806637B/en unknown
-
2020
- 2020-04-03 AU AU2020202381A patent/AU2020202381A1/en not_active Abandoned
- 2020-04-22 US US16/855,552 patent/US20200354426A1/en not_active Abandoned
-
2021
- 2021-08-26 US US17/412,811 patent/US20220041681A1/en not_active Abandoned
-
2022
- 2022-11-04 JP JP2022177486A patent/JP2023011864A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7237590B6 (en) | 2023-03-28 |
| WO2017153575A1 (en) | 2017-09-14 |
| JP2019510014A (en) | 2019-04-11 |
| NZ746784A (en) | 2022-11-25 |
| BR112018067731A2 (en) | 2019-01-08 |
| SG10202109721PA (en) | 2021-10-28 |
| KR102460198B1 (en) | 2022-10-31 |
| AR107890A1 (en) | 2018-06-28 |
| KR20180120739A (en) | 2018-11-06 |
| US10676517B2 (en) | 2020-06-09 |
| TWI793069B (en) | 2023-02-21 |
| EP3426284A1 (en) | 2019-01-16 |
| JP2023011864A (en) | 2023-01-24 |
| MY191321A (en) | 2022-06-15 |
| KR20220150416A (en) | 2022-11-10 |
| MX2018010640A (en) | 2019-06-13 |
| US20220041681A1 (en) | 2022-02-10 |
| US20190185537A1 (en) | 2019-06-20 |
| ZA201806637B (en) | 2019-07-31 |
| CA3015922A1 (en) | 2017-09-14 |
| IL261528B2 (en) | 2023-09-01 |
| EA201891946A1 (en) | 2019-04-30 |
| CN108697769A (en) | 2018-10-23 |
| AU2020202381A1 (en) | 2020-04-30 |
| AU2017229530A1 (en) | 2018-10-25 |
| EP3426284B1 (en) | 2024-05-08 |
| IL261528B1 (en) | 2023-05-01 |
| AU2017229530B2 (en) | 2020-05-07 |
| TW201733613A (en) | 2017-10-01 |
| IL261528A (en) | 2018-10-31 |
| US20200354426A1 (en) | 2020-11-12 |
| JP7237590B2 (en) | 2023-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201903167QA (en) | Compounds and methods for reducing atxn3 expression | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201908275XA (en) | Peptides and methods for the treatment of diabetes | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201809534UA (en) | Methods of treating autoimmune disease using allogeneic t cells |